Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | KIF11 | P52732 | 4/20 | 0.42 |
| ▸ | PRF1 | P14222 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | WRN | Q14191 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4554054 | 0.86 | KIF11 (0.40) | CYP2A6HDAC6KIF11PRF1HDAC4 | |
| SCHEMBL1197836 | 0.85 | CYP2A6 (0.51) | CYP2A6HDAC6MEN1ALDH1A1GLA | |
| SCHEMBL2242502 | 0.82 | KIF11 (0.39) | CYP2A6HDAC6KIF11PRF1HDAC4 | |
| SCHEMBL27961778 | 0.80 | KIF11 (0.52) | ALDH1A1KIF11PRF1 | |
| SCHEMBL14705447 | 0.80 | KIF11 (0.52) | ALDH1A1KIF11PRF1 | |
| SCHEMBL22340142 | 0.80 | PSEN1 (0.49) | HDAC6MEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL28280412 | 0.79 | ALDH1A1 (0.52) | CYP2A6HDAC6MEN1ALDH1A1GLA | |
| SCHEMBL14705469 | 0.78 | KIF11 (0.50) | KIF11PRF1WRN | |
| SCHEMBL4551879 | 0.78 | PRF1 (0.42) | CYP2A6HDAC6KIF11PRF1HDAC4 | |
| SCHEMBL25165734 | 0.77 | KIF11 (0.54) | KIF11PRF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090176863-A1 | THIOPHENE DERIVATIVE PPAR MODULATORS | MANTLO NATHAN BRYAN | 2009-07-09 | — | — | US | disclosed |
| WO-2008030520-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| US-7091237-B2 | Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060094768-A1 | Thiophene derivative ppar modulators | ELI LILLY AND COMPANY | 2006-05-04 | — | — | US | disclosed |
| EP-1583754-A1 | THIOPHENE DERIVATIVE PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1581521-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1392674-B1 | FURAN AND THIOPHENE DERIVATIVES THAT ACTIVATE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | SMITHKLINE BEECHAM CORP (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20040157890-A1 | Furan and thiophene derivatives that activate human peroxisome profilerator activated receptors | GLAXO GROUP LIMITED (GB) | 2004-08-12 | — | — | US | disclosed |
| WO-2004063190-A1 | FUSED HETEROCYCLIC DERIVATES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004063184-A1 | THIOPHENE DERIVATIVE PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157890-A1 | Furan and thiophene derivatives that activate human peroxisome profilerator activated receptors | PPARG, PPARD, PPARA | CYP2A6 282/4885HDAC6 1897/4885MEN1 4754/4885 |
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | GPR119, GPR55, GPR65 | CYP2A6 700/4885HDAC6 1454/4885MEN1 2521/4885 |
| US-20090176863-A1 | THIOPHENE DERIVATIVE PPAR MODULATORS | PPARA, PPARG, PPARD | CYP2A6 163/4885HDAC6 747/4885MEN1 4884/4885 |
| US-20060094768-A1 | Thiophene derivative ppar modulators | PPARA, PPARG, PPARD | CYP2A6 164/4885HDAC6 765/4885MEN1 4884/4885 |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | PPARG, PPARA, PPARD | CYP2A6 491/4885HDAC6 582/4885MEN1 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.